Sangamo Therapeutics, Inc. (SGMO) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sangamo Therapeutics, Inc. (SGMO) trades at $0.074 with AI Score 17/100 (Grade F). Sangamo Therapeutics, Inc. Market cap: $30.7M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: May 10, 2026Analyst Coverage for SGMO: SGMO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SGMO against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SGMO: 2/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Sangamo Therapeutics, Inc. (SGMO) Healthcare & Pipeline Overview
Sangamo Therapeutics, Inc. pioneers genomic medicines using gene therapy, cell therapy, genome editing, and regulation technologies. With a focus on zinc finger protein (ZFP) technology, they are developing treatments for hemophilia A, Fabry disease, and sickle cell disease, positioning them as an innovator in the biotechnology sector.
What Is the Investment Thesis for SGMO?
Sangamo Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's diverse pipeline of genomic medicines, particularly SB-525 in Phase III trials for hemophilia A, offers significant potential upside. Successful clinical trial outcomes and subsequent regulatory approvals could drive substantial revenue growth. However, the company's negative profit margin of -310.8% highlights its reliance on partnerships and future product revenue. Key catalysts include clinical trial readouts for ST-920 and SAR445136. The company's beta of 1.50 indicates higher volatility compared to the market. Investment hinges on the successful execution of clinical programs and strategic collaborations.
Based on FMP financials and quantitative analysis
SGMO Key Highlights
- Market capitalization of $30.7M reflects the company's current valuation and growth potential in the genomic medicine space.
- Gross margin of 80.8% indicates strong potential profitability upon commercialization of successful therapies.
- Profit margin of -310.8% highlights the significant R&D expenses associated with clinical-stage biotechnology companies.
- SB-525 in Phase III AFFINE clinical trial for hemophilia A represents a near-term value driver.
- Collaborative partnerships with Biogen, Pfizer, and Sanofi provide financial support and validation of Sangamo's technology.
Who Are SGMO's Competitors?
SGMO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | $47.53 | +0.61% | $4.58B | 44 |
| EDIT Editas Medicine, Inc. | $2.73 | -1.80% | $267M | — |
| GBIO Generation Bio Co. | $5.34 | +0.00% | $36.0M | 69 |
| BLRX BioLineRx Ltd. | $2.86 | +0.41% | $12.4M | 69 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.35% | $7.58M | 72 |
| ORMP Oramed Pharmaceuticals Inc. | $4.16 | +3.48% | $170M | 75 |
| CGEN Compugen Ltd. | $2.34 | -3.31% | $221M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SGMO's Key Strengths?
- Proprietary ZFP technology platform.
- Diverse pipeline of genomic medicines.
- Strategic partnerships with leading pharmaceutical companies.
- Strong intellectual property portfolio.
What Are SGMO's Weaknesses?
- Negative profit margin and reliance on external funding.
- Clinical trial risks and regulatory hurdles.
- Competition from other gene editing companies.
- Limited commercialized products.
What Could Drive SGMO Stock Higher?
- Data readout from Phase III AFFINE clinical trial for SB-525 in Hemophilia A.
- Data readout from Phase I/II STAAR clinical trials for ST-920 in Fabry disease.
- Advancement of SAR445136 in Phase I/II PRECIZN-1 clinical trials for sickle cell disease.
- Continued progress in strategic partnerships with Biogen, Pfizer, and Sanofi.
What Are the Key Risks for SGMO?
- Financial-distress signal — its Altman Z-Score of -45.05 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays could negatively impact the company's pipeline and valuation.
- Regulatory setbacks or rejection of marketing applications could hinder commercialization efforts.
- Competition from other gene editing companies could erode market share.
- Dependence on strategic partnerships for funding and expertise poses a risk if collaborations are terminated or unsuccessful.
What Are the Growth Opportunities for SGMO?
- Advancement of SB-525 for Hemophilia A: The Phase III AFFINE clinical trial for SB-525 represents a significant near-term growth opportunity. Hemophilia A is a large market with unmet medical needs, and positive trial results could lead to regulatory approval and commercialization, potentially generating substantial revenue. The global hemophilia A market is projected to reach $15 billion by 2028.
- Development of ST-920 for Fabry Disease: ST-920, a gene therapy in Phase I/II clinical trials for Fabry disease, offers another growth avenue. Fabry disease is a rare genetic disorder with limited treatment options. Successful development and commercialization of ST-920 could capture a significant share of the Fabry disease market, estimated at $2 billion.
- Expansion of Cell Therapy Programs: Sangamo's cell therapy programs, including SAR445136 for sickle cell disease and KITE-037 for cancer, represent long-term growth opportunities. Cell therapy is a rapidly growing field with the potential to revolutionize the treatment of various diseases. The global cell therapy market is projected to reach $80 billion by 2030.
- Strategic Partnerships: Sangamo's collaborative partnerships with Biogen, Pfizer, and Sanofi provide access to funding, expertise, and resources, accelerating the development and commercialization of its genomic medicines. These partnerships also validate Sangamo's technology and enhance its credibility in the industry. Continued strategic alliances will be crucial for future growth.
- Expansion into New Therapeutic Areas: Sangamo's pipeline includes programs targeting tauopathies and synucleinopathies, including Parkinson's disease. These programs represent opportunities to expand into new therapeutic areas with significant unmet medical needs. Success in these areas could diversify Sangamo's revenue streams and drive long-term growth. The market for Parkinson's disease treatment is projected to reach $6 billion by 2027.
What Opportunities Does SGMO Have?
- Advancement of clinical-stage programs to commercialization.
- Expansion into new therapeutic areas.
- Further strategic partnerships and collaborations.
- Increased adoption of genomic medicines.
What Threats Does SGMO Face?
- Clinical trial failures and regulatory setbacks.
- Competition from established pharmaceutical companies.
- Patent disputes and intellectual property challenges.
- Changes in healthcare regulations and reimbursement policies.
What Are SGMO's Competitive Advantages?
- Proprietary zinc finger protein (ZFP) technology platform.
- Extensive intellectual property portfolio in genomic medicine.
- Established partnerships with leading pharmaceutical companies.
- Clinical-stage pipeline of genomic medicines targeting unmet medical needs.
What Does SGMO Do?
Sangamo Therapeutics, Inc., founded in 1995 and headquartered in Brisbane, California, is a clinical-stage biotechnology company dedicated to translating scientific advancements into genomic medicines. The company's core focus lies in developing transformative treatments using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. Sangamo's pioneering work centers around its zinc finger protein (ZFP) technology, a platform for creating zinc finger nucleases that modify DNA sequences by adding or knocking out specific genes, and ZFP transcription factors that modulate gene expression. Sangamo's pipeline includes several clinical-stage programs. SB-525 is currently in Phase III clinical trials for the treatment of hemophilia A. ST-920, a gene therapy, is in Phase I/II clinical trials for Fabry disease. SAR445136, a cell therapy, is in Phase I/II clinical trials for sickle cell disease. Additionally, Sangamo is developing TX200 for kidney transplant rejection, KITE-037 for cancer, ST-501 for tauopathies, and ST-502 for synucleinopathies, including Parkinson's disease. The company collaborates with industry leaders such as Biogen, Kite Pharma, Pfizer, and Sanofi, leveraging partnerships to advance its research and development efforts. Formerly known as Sangamo BioSciences, Inc., the company rebranded as Sangamo Therapeutics, Inc. in January 2017 to reflect its expanded focus on therapeutic applications of its genomic technologies.
What Products and Services Does SGMO Offer?
- Develop genomic medicines using gene therapy.
- Develop genomic medicines using cell therapy.
- Develop genomic medicines using genome editing.
- Develop genomic medicines using genome regulation.
- Utilize zinc finger protein (ZFP) technology to modify DNA sequences.
- Develop treatments for hemophilia A, Fabry disease, and sickle cell disease.
- Collaborate with pharmaceutical companies to advance research and development.
How Does SGMO Make Money?
- Develops and out-licenses genomic medicine technologies.
- Generates revenue through collaborative partnerships with pharmaceutical companies.
- Aims to generate revenue through commercialization of proprietary therapies.
- Focuses on R&D to expand its pipeline of genomic medicines.
What Industry Does SGMO Operate In?
Sangamo Therapeutics operates within the rapidly evolving biotechnology industry, specifically in the genomic medicine sector. This sector is characterized by high growth potential driven by advancements in gene therapy, cell therapy, and genome editing technologies. The competitive landscape includes companies like CRISPR Therapeutics and Editas Medicine, which are also focused on genome editing.
Who Are SGMO's Key Customers?
- Patients with genetic diseases such as hemophilia A, Fabry disease, and sickle cell disease.
- Pharmaceutical companies seeking to develop and commercialize genomic medicines.
- Research institutions and academic centers.
Company Profile
Sangamo Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Richmond, US. The company is led by CEO Alexander D. Macrae Ch.B. SGMO has traded publicly since 2000.
Sangamo Therapeutics, Inc. (SGMO) Valuation Context
Relative to its peer group, SGMO's quantitative score of 17/100 is below the peer average of 63/100.
F-Score 1/9Financial Health
Sangamo Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -45.05 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Sangamo Therapeutics, Inc. revenue of about $67.6M for fiscal 2026, with EPS near $-0.19.
SGMO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the potential of their gene therapy programs.
- Community sentiment has shifted positively as recent clinical trial results have shown promise, fueling optimism among investors.
- Sangamo's partnerships with larger pharmaceutical companies are gaining traction, enhancing credibility and expanding their market reach.
- The growing interest in gene editing technologies positions Sangamo favorably within a rapidly evolving biotech landscape.
Bear Case
- Concerns about the pace of clinical trial advancements have surfaced, leading some investors to question the company's ability to deliver timely results.
- Community sentiment reflects skepticism about the competitive landscape, with several biotech firms advancing similar technologies.
- Recent regulatory challenges in the biotech sector may create additional hurdles for Sangamo, impacting investor confidence.
- Market perception remains cautious as the company has yet to achieve significant revenue, raising doubts about its long-term viability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SGMO Latest News
-
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
benzinga · Jun 23, 2026
-
Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics
MT Newswires · Jun 23, 2026
-
Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's Workforce
benzinga · Jun 23, 2026
-
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy
benzinga · Jun 12, 2026
SGMO Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGMO.
Price Targets
Wall Street price target analysis for SGMO.
SGMO MoonshotScore
What does this score mean?
The MoonshotScore rates SGMO 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Latest News
Sangamo Bankruptcy Puts Gene Therapy Platforms In Play, Eli Lilly And Astellas Circle
Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics
Sangamo Therapeutics Files For Chapter 11 Bankruptcy, Secures Up To $30M In Debtor-In-Possession Financing; Launches Court-Supervised Asset Sale Process With Eli Lilly And Astellas As Stalking Horse Bidders For Key Gene Therapy, Genome Editing, And Fabry Disease Assets; Expects Restructuring To Result In Elimination Of About 51 Roles In U.S., Or About 40% Of Company's Workforce
Deal Dispatch: Carlyle Buys Chung Ho Group, Second Nature Brands Acquires Tillamook Country Smoker, GoHealth Bankruptcy
Leadership: Alexander D. Macrae Ch.B
Chief Executive Officer
Alexander D. Macrae Ch.B serves as the Chief Executive Officer of Sangamo Therapeutics, bringing extensive experience in the pharmaceutical and biotechnology industries. His background includes a medical degree and significant leadership roles in various companies. He has a proven track record in driving strategic growth and innovation within the healthcare sector. His expertise spans clinical development, regulatory affairs, and commercialization of novel therapies.
Track Record: Since becoming CEO, Alexander D. Macrae Ch.B has focused on advancing Sangamo's pipeline of genomic medicines and strengthening its strategic partnerships. Key milestones under his leadership include the progression of SB-525 into Phase III clinical trials and the expansion of collaborations with major pharmaceutical companies. He has also overseen efforts to optimize the company's research and development programs.
SGMO OTC Market Information
SGMO trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
SGMO Healthcare Stock FAQ
What does the AI Score mean for SGMO?
SGMO holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines through gene therapy, cell therapy, genome editing, and genome regulation. Their …
What does Sangamo Therapeutics, Inc. do?
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genomic medicines through gene therapy, cell therapy, genome editing, and genome regulation. The company's core technology revolves around its zinc finger protein (ZFP) platform, which allows for precise modification of DNA sequences.
What do analysts say about SGMO stock?
Analyst coverage of SGMO stock reflects a mixed outlook, acknowledging the high-risk, high-reward nature of clinical-stage biotechnology companies. Valuations are heavily dependent on the successful progression of its clinical pipeline, particularly SB-525 for hemophilia A. While the company's ZFP technology is viewed favorably, analysts also highlight the risks associated with clinical trials, regulatory approvals, and competition.
What are the main risks for SGMO?
The main risks for Sangamo Therapeutics include clinical trial failures, regulatory setbacks, and competition. Clinical trial failures could significantly impact the company's pipeline and valuation. Regulatory setbacks or rejection of marketing applications could hinder commercialization efforts. Competition from other gene editing companies could erode market share.
What are the key factors to evaluate for SGMO?
Sangamo Therapeutics, Inc. (SGMO) holds an AI score of 17/100 (low). Not financial advice.
How frequently does SGMO data refresh on this page?
SGMO's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SGMO's recent stock price performance?
Sangamo Therapeutics, Inc. (SGMO) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary ZFP technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGMO overvalued or undervalued right now?
Sangamo Therapeutics, Inc. (SGMO) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SGMO before investing?
Before investing in Sangamo Therapeutics, Inc. (SGMO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-10.
- Clinical trial outcomes are inherently uncertain.
- Market projections are subject to change.